CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 22,639,300 shares, a growth of 6.4% from the January 15th total of 21,272,500 shares. Based on an average daily volume of 11,699,700 shares, the days-to-cover ratio is currently 1.9 days.

CytoDyn Trading Up 0.2 %

CytoDyn stock traded up $0.00 during trading hours on Friday, reaching $0.22. 1,991,689 shares of the company were exchanged, compared to its average volume of 4,342,034. The firm has a market cap of $267.36 million, a price-to-earnings ratio of -21.73 and a beta of 0.01. The stock has a 50-day moving average of $0.16 and a 200 day moving average of $0.15. CytoDyn has a 12 month low of $0.10 and a 12 month high of $0.32.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.